A plural role for lipids in motor neuron diseases: Energy, signaling and structure

Frontiers in Cellular Neuroscience

Volumn 8, Issue FEB, 2014, Pages

  Schmitt, Florent ^a,b   Hussain, Ghulam ^a,b   Dupuis, Luc ^a,b   Loeffler, Jean Philippe ^a,b   Henriques, Alexandre ^a,b  

^a Laboratoire des Mecanismes Centraux et Peripheriques de la Neurodegenerescence   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

ALS; Lipid; Metabolism; Motor neuron; SBMA; SMA

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; PIOGLITAZONE; PROSTAGLANDIN E2; TRIACYLGLYCEROL;

AMYOTROPHIC LATERAL SCLEROSIS; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY METABOLISM; EXERCISE; HUMAN; HYPERMETABOLISM; INTRACELLULAR SIGNALING; KENNEDY DISEASE; LIPID METABOLISM; MEMBRANE FLUIDITY; MITOCHONDRION; MOTOR NEURON DISEASE; NERVE DEGENERATION; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MUSCULAR ATROPHY; REVIEW; SPINAL MUSCULAR ATROPHY;

EID: 84894252984     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00025     Document Type: Review

References (124)

1. Akasako, Y., Nara, K., Nagai, Y., and Hashimoto, Y. (2011). Inhibition of ganglioside synthesis reduces the neuronal survival activity of astrocytes. Neurosci. Lett. 488, 199-203. doi: 10.1016/j.neulet.2010.11.029
2. Arsenault, D., Julien, C., Tremblay, C., and Calon, F. (2011). DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS ONE 6:e17397. doi: 10.1371/journal.pone.0017397
3. Atkin, J. D., Scott, R. L., West, J. M., Lopes, E., Quah, A. K., and Cheema, S. S. (2005). Properties of slow- and fast-twitch muscle fibres in a mouse model of amyotrophic lateral sclerosis. Neuromuscul. Disord. 15, 377-388. doi: 10.1016/j.nmd.2005.02.005.
4. Barroso, E., Rodriguez-Calvo, R., Serrano-Marco, L., Astudillo, A. M., Balsinde, J., Palomer, X., et al. (2011). The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. Endocrinology 152, 1848-1859. doi: 10.1210/en.2010-1468.
5. Bazan, N. G., Musto, A. E., and Knott, E. J. (2011). Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol. Neurobiol. 44, 216-222. doi: 10.1007/s12035- 011-8200-6
6. Bebee, T. W., Dominguez, C. E., and Chandler, D. S. (2012). Mouse models of SMA: tools for disease characterization and therapeutic development. Hum. Genet. 131, 1277-1293. doi: 10.1007/s00439-012-1171-5.
7. Bello-Haas, V. D., Florence, J. M., Kloos, A. D., Scheirbecker, J., Lopate, G., Hayes, S. M., et al. (2007). A randomized controlled trial of resistance exercise in individuals with alS. Neurology 68, 2003-2007. doi: 10.1212/01.wnl.0000264418.92308.a4.
8. Blasco, H., Corcia, P., Moreau, C., Veau, S., Fournier, C., Vourc'h P., et al. (2010). 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS ONE 5:e13223. doi: 10.1371/journal.pone.0013223.
9. Bradley, W. G. (1984). Double-blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv. Exp. Med. Biol. 174, 565-573. doi: 10.1007/978-1-4684-1200-0_47.
10. Bras, J., Singleton, A., Cookson, M. R., and Hardy, J. (2008). Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J. 275, 5767-5773. doi: 10.1111/j.1742-4658.2008.06709.x
11. Braun, M. M., Osecheck, M., and Joyce, N. C. (2012). Nutrition assessment and management in amyotrophic lateral sclerosis. Phys. Med. Rehabil. Clin. N. Am. 23, 751-771. doi: 10.1016/j.pmr.2012.08.006.
12. Brooks, B. P., and Fischbeck, K. H. (1995). Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci. 18, 459-461. doi: 10.1016/0166-2236(95)94497-S
13. Brooks, B. R., Juhasz-Poscine, K., Waclawik, A., Sanjak, M., Belden, D., Roelke, K., et al. (2000). Mosaic chemotherapy strategies for developing alS/MND therapeutic approaches: beta-2 adrenergic agonists. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1(Suppl. 4), 45-53. discussion: 53-54. doi: 10.1080/14660820050515700-1.
14. Brugg, B., Michel, P. P., Agid, Y., and Ruberg, M. (1996). Ceramide induces apoptosis in cultured mesencephalic neurons. J. Neurochem. 66, 733-739. doi: 10.1046/j.1471-4159.1996.66020733.x
15. Butchbach, M. E., Rose, F. F. Jr., Rhoades, S., Marston, J., McCrone, J. T., Sinnott, R., et al. (2010). Effect of diet on the survival and phenotype of a mouse model for spinal muscular atrophy. Biochem. Biophys. Res. Commun. 391, 835-840. doi: 10.1016/j.bbrc.2009.11.148.
16. Car, H., Zendzian-Piotrowska, M., Fiedorowicz, A., Prokopiuk, S., Sadowska, A., and Kurek, K. (2012). [The role of ceramides in selected brain pathologies: ischemia/hypoxia, Alzheimer disease]. Postepy Hig. Med. Dosw. (Online) 66, 295-303. doi: 10.5604/17322693.999024.
17. Carreras, I., Yuruker, S., Aytan, N., Hossain, L., Choi, J. K., Jenkins, B. G., et al. (2010). Moderate exercise delays the motor performance decline in a transgenic model of alS. Brain Res. 1313, 192-201. doi: 10.1016/j.brainres. 2009.11.051
18. Chio, A., Calvo, A., Ilardi, A., Cavallo, E., Moglia, C., Mutani, R., et al. (2009). Lower serum lipid levels are related to respiratory impairment in patients with alS. Neurology 73, 1681-1685. doi: 10.1212/WNL.0b013e3181c1df1e
19. Cozzolino, M., Ferri, A., Valle, C., and Carri, M. T. (2013). Mitochondria and alS: implications from novel genes and pathways. Mol. Cell. Neurosci. 55, 44-49. doi: 10.1016/j.mcn.2012.06.001.
20. Crawford, T. O., Sladky, J. T., Hurko, O., Besner-Johnston, A., and Kelley, R. I. (1999). Abnormal fatty acid metabolism in childhood spinal muscular atrophy. Ann. Neurol. 45, 337-343. doi: 10.1002/1531-8249(199903)45:3<337::AID-ANA9>3.0.C0;2-U
21. Crugnola, V., Lamperti, C., Lucchini, V., Ronchi, D., Peverelli, L., Prelle, A., et al. (2010). Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol. 67, 849-854. doi: 10.1001/arch-neurol.2010.128
22. Cutler, R. G., Pedersen, W. A., Camandola, S., Rothstein, J. D., and Mattson, M. P. (2002). Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 52, 448-457. doi: 10.1002/ana.10312.
23. Da Cruz, S., Parone, P. A., Lopes, V. S., Lillo, C., McAlonis-Downes, M., Lee, S. K., et al. (2012). Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited alS. CellMetab. 15, 778-786. doi: 10.1016/j.cmet.2012.03.019
24. de Almeida, J. P., Silvestre, R., Pinto, A. C., and de Carvalho, M. (2012). Exercise and amyotrophic lateral sclerosis. Neurol. Sci. 33, 9-15. doi: 10.1007/s10072- 011-0921-9
25. Deforges, S., Branchu, J., Biondi, O., Grondard, C., Pariset, C., Lecolle, S., et al. (2009). Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 587, 3561-3572. doi: 10.1113/jphys- iol.2009.169748
26. Deng, H. X., Zhai, H., Bigio, E. H., Yan, J., Fecto, F., Ajroud, K., et al. (2010). FUS-immunoreactive inclusions are a common feature in sporadic and non- SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 67, 739-748. doi: 10.1002/ana.22051
27. Desport, J. C., Preux, P. M., Magy, L., Boirie, Y., Vallat, J. M., Beaufrere, B., et al. (2001). Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 74, 328-334.
28. Dobrzyn, A., Dobrzyn, P., Lee, S. H., Miyazaki, M., Cohen, P., Asilmaz, E., et al. (2005). Stearoyl-CoA desaturase-1 deficiency reduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing beta-oxidation in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 288, E599-E607. doi: 10.1152/ajpendo.00439.2004.
29. Dorst, J., Cypionka, J., and Ludolph, A. C. (2013). High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 533-536. doi: 10.3109/21678421.2013.823999.
30. Dorst, J., Kuhnlein, P., Hendrich, C., Kassubek, J., Sperfeld, A. D., and Ludolph, A. C. (2011). Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J. Neurol. 258, 613-617. doi: 10.1007/s00415-010-5805-z
31. Drory, V. E., Goltsman, E., Reznik, J. G., Mosek, A., and Korczyn, A. D. (2001). The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 191, 133-137. doi: 10.1016/S0022-510X(01)00610-4.
32. Dupuis, L. (2013). Mitochondrial quality control in neurodegenerative diseases. Biochimie. doi: 10.1016/j.biochi.2013.07.033. [Epub ahead of print].
33. Dupuis, L., Corcia, P., Fergani, A., Gonzalez De Aguilar, J. L., Bonnefont- Rousselot, D., Bittar, R., et al. (2008). Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70, 1004-1009. doi: 10.1212/01.wnl.0000285080.70324.27.
34. Dupuis, L., Dengler, R., Heneka, M. T., Meyer, T., Zierz, S., Kassubek, J., et al. (2012). A randomized, double blind, placebo-controlled trial ofpioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE 7:e37885. doi: 10.1371/journal.pone.0037885.
35. Dupuis, L., and Loeffler, J. P. (2009). Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 9, 341-346. doi: 10.1016/j.coph.2009.03.007.
36. Dupuis, L., Oudart, H., Rene, F., Gonzalez de Aguilar, J. L., and Loeffler, J. P. (2004). Evidence for defective energyhomeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. U.S.A. 101, 11159-11164. doi: 10.1073/pnas.0402026101.
37. Dupuis, L., Pradat, P. F., Ludolph, A. C., and Loeffler, J. P. (2011). Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 10, 75-82. doi: 10.1016/S1474-4422(10)70224-6.
38. Dupuis, L., di Scala, F., Rene, F., de Tapia, M., Oudart, H., Pradat, P. F., et al. (2003). Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J. 17, 2091-2093. doi: 10.1096/fj.02-1182fje
39. Echaniz-Laguna, A., Zoll, J., Ribera, F., Tranchant, C., Warter, J. M., Lonsdorfer, J., et al. (2002). Mitochondrial respiratorychain function in skeletal muscle of alS patients. Ann. Neurol. 52, 623-627. doi: 10.1002/ana.10357.
40. Eschbach, J., Schwalenstocker, B., Soyal, S., Bayer, H., Wiesner, D., Akimoto, C., et al. (2013). PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Hum. Mol. Genet. 22, 3477-3484. doi: 10.1093/hmg/ddt202.
41. Fergani, A., Oudart, H., Gonzalez De Aguilar, J. L., Fricker, B., Rene, F., Hocquette, J. F., et al. (2007). Increased peripheral lipidclearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res. 48, 1571-1580. doi: 10.1194/jlr.M700017- JLR200
42. Filippov, V., Song, M. A., Zhang, K., Vinters, H. V., Tung, S., Kirsch, W. M., et al. (2012). Increased ceramide in brains with Alzheimer's and other neu- rodegenerative diseases. J. Alzheimers. Dis. 29, 537-547. doi: 10.3233/JAD-2011- 111202
43. Fischbeck, K. H., Lieberman, A., Bailey, C. K., Abel, A., and Merry, D. E. (1999). Androgen receptor mutation in Kennedy's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 1075-1078. doi: 10.1098/rstb.1999.0461.
44. France-Lanord, V., Brugg, B., Michel, P. P., Agid, Y., and Ruberg, M. (1997). Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. J. Neurochem. 69, 1612-1621. doi: 10.1046/j.1471-4159.1997.69041612.x
45. Funalot, B., Desport, J. C., Sturtz, F., Camu, W., and Couratier, P. (2009). High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph. LateralScler. 10, 113-117. doi: 10.1080/17482960802295192.
46. Gallo, V., Wark, P.A., Jenab, M., Pearce, N., Brayne, C., Vermeulen, R., et al. (2013). Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 80, 829-838. doi: 10.1212/WNL.0b013e3182840689.
47. Gerber, Y. N., Sabourin, J. C., Hugnot, J. P., and Perrin, F. E. (2012). Unlike physical exercise, modified environment increases the lifespan of SOD1G93A mice however both conditions induce cellular changes. PLoS ONE 7:e45503. doi: 10.1371/journal.pone.0045503.
48. Gonzalez de Aguilar, J. L., Niederhauser-Wiederkehr, C., Halter, B., De Tapia, M., Di Scala, F., Demougin, P., et al. (2008). Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol. Genomics 32, 207-218. doi: 10.1152/physiolgenomics.00017.2007.
49. Gordon, T., Tyreman, N., Li, S., Putman, C. T., and Hegedus, J. (2010). Functional over-load saves motor units in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 37, 412-422. doi: 10.1016/j.nbd.2009.10.021.
50. Guzman, M., and Blazquez, C. (2004). Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins Leukot. Essent. Fatty Acids 70, 287-292. doi: 10.1016/j.plefa.2003.05.001.
51. Hallett, M., Harrington, H., Tyler, H. R., Flood, T., and Slater, N. (1984). Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy. Adv. Exp. Med. Biol. 174, 575-579. doi: 10.1007/978-1-4684-1200-0_48.
52. Hamadeh, M. J., Rodriguez, M. C., Kaczor, J. J., and Tarnopolsky, M. A. (2005). Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31, 214-220. doi: 10.1002/mus.20255.
53. Handschin, C. (2010). Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor gamma coactivator 1alpha. J. Recept. Signal Transduct. Res. 30, 376-384. doi: 10.3109/10799891003641074.
54. Hegedus, J., Putman, C. T., and Gordon, T. (2007). Time course of preferential motor unit loss in the SOD1. G93A mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 28, 154-164. doi: 10.1016/j.nbd. 2007.07.003
55. Hussain, G., Schmitt, F., Henriques, A., Lequeu, T., Rene, F., Bindler, F., et al. (2013). Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury. PLoS ONE 8:e64525. doi: 10.1371/journal.pone.0064525.
56. Ilieva, E. V., Ayala, V., Jove, M., Dalfo, E., Cacabelos, D., Povedano, M., et al. (2007). Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 130, 3111-3123. doi: 10.1093/brain/awm190.
57. Ilzecka, J. (2003). Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 108, 125-129. doi: 10.1034/j.1600- 0404.2003.00102.x
58. Jawaid, A., Murthy, S. B., Wilson, A. M., Qureshi, S. U., Amro, M. J., Wheaton, M., et al. (2010). A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in alS. Amyotroph. Lateral Scler. 11, 542-548. doi: 10.3109/17482968.2010.482592.
59. Kanner, J., German, J. B., and Kinsella, J. E. (1987). Initiation of lipid peroxidation in biological systems. Crit. Rev. Food Sci. Nutr. 25, 317-364. doi: 10.1080/10408398709527457.
60. Katsuno, M., Adachi, H., Inukai, A., and Sobue, G. (2003). Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA). Cytogenet. Genome Res. 100, 243-251. doi: 10.1159/000072860.
61. Kim, S. M., Kim, H., Kim, J. E., Park, K. S., Sung, J. J., Kim, S. H., et al. (2011). Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS ONE 6:e17985. doi: 10.1371/journal.pone. 0017985
62. Kim, Y. J., Nakatomi, R., Akagi, T., Hashikawa, T., and Takahashi, R. (2005). Unsaturated fatty acids induce cytotoxic aggregate formation of amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutants. J. Biol. Chem. 280, 21515-21521. doi: 10.1074/jbc.M502230200.
63. Kissel, J. T., Scott, C. B., Reyna, S. P., Crawford, T. O., Simard, L. R., Krosschell, K. J., et al. (2011). SMA CARNIVal TRIal PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE 6:e21296. doi: 10.1371/journal.pone.0021296
64. Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., and Beal, M. F. (2004). Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. 88, 576-582. doi: 10.1046/j.1471-4159.2003.02160.x
65. Kumar, A., Bala, L., Kalita, J., Misra, U. K., Singh, R. L., Khetrapal, C. L., et al. (2010). Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin. Chim. Acta 411, 563-567. doi: 10.1016/j.cca.2010.01.016.
66. Laaksovirta, H., Peuralinna, T., Schymick, J. C., Scholz, S. W., Lai, S. L., Myllykangas, L., et al. (2010). Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 9, 978-985. doi: 10.1016/S1474-4422(10)70184-8.
67. LaManna, J. C., Salem, N., Puchowicz, M., Erokwu, B., Koppaka, S., Flask, C., et al. (2009). Ketones suppress brain glucose consumption. Adv. Exp. Med. Biol. 645, 301-306. doi: 10.1007/978-0-387-85998-9_45.
68. Lang, T. (2007). SNARE proteins and "membrane rafts." J. Physiol. 585, 693-698. doi: 10.1113/jphysiol.2007.134346.
69. Liang, X., Wang, Q., Shi, J., Lokteva, L., Breyer, R. M., Montine, T. J., et al. (2008). The prostaglandin E2. EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 64, 304-314. doi: 10.1002/ana.21437.
70. Lin, J., Handschin, C., and Spiegelman, B. M. (2005). Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370. doi: 10.1016/j.cmet.2005.05.004.
71. Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., et al. (2002). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797-801. doi: 10.1038/nature00904.
72. Lindauer, E., Dupuis, L., Muller, H. P., Neumann, H., Ludolph, A. C., and Kassubek, J. (2013). Adipose tissue distribution predicts survival in amyotrophic lateral sclerosis. PLoS ONE 8:e67783. doi: 10.1371/journal.pone.0067783.
73. Lingwood, D., and Simons, K. (2010). Lipid rafts as a membrane-organizing principle. Science 327, 46-50. doi: 10.1126/science.1174621.
74. Mackenzie, I. R., Bigio, E. H., Ince, P. G., Geser, F., Neumann, M., Cairns, N. J., et al. (2007). Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 61, 427-434. doi: 10.1002/ana.21147.
75. Mahajan, K. R., Bach, J. R., Saporito, L., and Perez, N. (2012). Diaphragm pacing and noninvasive respiratory management of amyotrophic lateral sclerosis/motor neuron disease. Muscle Nerve 46, 851-855. doi: 10.1002/mus.23663.
76. Marin, B., Desport, J. C., Kajeu, P., Jesus, P., Nicolaud, B., Nicol, M., et al. (2011). Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J. Neurol. Neurosurg. Psychiatry 82, 628-634. doi: 10.1136/jnnp.2010.211474.
77. Maswood, N., Young, J., Tilmont, E., Zhang, Z., Gash, D. M., Gerhardt, G. A., et al. (2004). Caloric restriction increases neurotrophic factor levels and attenuates neurochemical andbehavioral deficits inaprimatemodel ofParkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 18171-18176. doi: 10.1073/pnas.0405831102.
78. Mattson, M. P., Cutler, R. G., and Camandola, S. (2007). Energy intake and amyotrophic lateral sclerosis. Neuromolecular Med. 9, 17-20. doi: 10.1385/NMM:9:1:17.
79. Miana-Mena, F. J., Piedrafita, E., Gonzalez-Mingot, C., Larrode, P., Munoz, M. J., Martinez-Ballarin, E., et al. (2011). Levels of membrane fluidity in the spinal cord and the brain in an animal model of amyotrophic lateral sclerosis. J. Bioenerg. Biomembr. 43, 181-186. doi: 10.1007/s10863-011-9348-5.
80. Miyazaki, M., and Esser, K. A. (2009). REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch. Am. J. Physiol. Cell Physiol. 296, C583-C592. doi: 10.1152/ajpcell.00464.2008.
81. Mizutani, K., Oka, N., Kusunoki, S., Kaji, R., Kanda, M., Akiguchi, I., et al. (2003). Amyotrophic lateral sclerosis with IgM antibody against gangliosides GM2 and GD2. Intern. Med. 42, 277-280. doi: 10.2169/internalmedicine.42.277.
82. Mo, K., Razak, Z., Rao, P., Yu, Z., Adachi, H., Katsuno, M., et al. (2010). Microarray analysis ofgene expression byskeletal muscle ofthree mouse models ofKennedy disease/spinal bulbar muscular atrophy. PLoS ONE 5:e12922. doi: 10.1371/jour- nal.pone.0012922
83. Muscaritoli, M., Kushta, I., Molfino, A., Inghilleri, M., Sabatelli, M., and Rossi Fanelli, F. (2012). Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition 28, 959-966. doi: 10.1016/j.nut.2012.01.011.
84. Ntambi, J. M., Miyazaki, M., Stoehr, J. P., Lan, H., Kendziorski, C. M., Yandell, B. S., et al. (2002). Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. U.S.A. 99, 11482-11486. doi: 10.1073/pnas.132384699.
85. Okamoto, K., Kihira, T., Kondo, T., Kobashi, G., Washio, M., Sasaki, S., et al. (2007). Nutritional status and risk of amyotrophic lateral sclerosis in Japan. Amyotroph. LateralScler. 8, 300-304. doi: 10.1080/17482960701472249.
86. Ozsoy, O., Seval-Celik, Y., Hacioglu, G., Yargicoglu, P., Demir, R., Agar, A., et al. (2011). The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem. Int. 59, 664-670. doi: 10.1016/j.neuint.2011.06.012.
87. Paganoni, S., Deng, J., Jaffa, M., Cudkowicz, M. E., and Wills, A. M. (2011). Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44, 20-24. doi: 10.1002/mus.22114.
88. Pasinetti, G. M., Bilski, A. E., and Zhao, W. (2013). Sirtuins as therapeutic targets ofalS. CellRes. 23, 1073-1074. doi: 10.1038/cr.2013.94.
89. Patel, B. P., Safdar, A., Raha, S., Tarnopolsky, M. A., and Hamadeh, M. J. (2010). Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of alS. PLoS ONE 5:e9386. doi: 10.1371/journal.pone.0009386.
90. Patel, N. V., Gordon, M. N., Connor, K. E., Good, R. A., Engelman, R. W., Mason, J., et al. (2005). Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995-1000. doi: 10.1016/j.neurobiolaging.2004.09.014.
91. Pehar, M., Vargas, M. R., Robinson, K. M., Cassina, P., Diaz-Amarilla, P. J., Hagen, T. M., et al. (2007). Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J. Neurosci. 27, 7777-7785. doi: 10.1523/JNEUROSCI.0823-07.2007.
92. Pisani, D. F., Leclerc, L., Jarretou, G., Marini, J. F., and Dechesne, C. A. (2005). SMHS1 is involved in oxidative/glycolytic-energy metabolism balance of muscle fibers. Biochem. Biophys. Res. Commun. 326, 788-793. doi: 10.1016/j.bbrc.2004.11.111.
93. Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., and Pasinetti, G. M. (2003). A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 17, 725-727. doi: 10.1096/fj.02-0876fje
94. Poruk, K. E., Davis, R. H., Smart, A. L., Chisum, B. S., Lasalle, B. A., Chan, G. M., et al. (2012). Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type, I. Neuromuscul. Disord. 22, 966-973. doi: 10.1016/j.nmd.2012. 04.008
95. Pradat, P. F., Dubourg, O., de Tapia, M., di Scala, F., Dupuis, L., Lenglet, T., et al. (2011). Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener. Dis. 9, 38-52. doi: 10.1159/000329723.
96. Pun, S., Santos, A. F., Saxena, S., Xu, L., and Caroni, P. (2006). Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 9, 408-419. doi: 10.1038/nn1653.
97. Rao, A., Asadi-Lari, M., Walsh, J., Wilcox, R., and Gray, D. (2006). Quality oflife in patientswithsigns andsymptoms ofheartfailure-does systolic function matter? J. Card. Fail. 12, 677-683. doi: 10.1016/j.cardfail.2006.08.004.
98. Reich-Slotky, R., Andrews, J., Cheng, B., Buchsbaum, R., Levy, D., Kaufmann, P., et al. (2013). Body mass index (BMI) as predictor of alSFRS-R score decline in alS patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 14, 212-216. doi: 10.3109/21678421.2013.770028.
99. Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H., and Gordon, J. W. (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 92, 689-693. doi: 10.1073/pnas.92.3.689.
100. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. doi: 10.1038/ 362059a0
101. Schmied, A., Pouget, J., and Vedel, J. P. (1999). Electromechanical coupling and synchronous firing of single wrist extensor motor units in sporadic amyotrophic lateral sclerosis. Clin. Neurophysiol. 110, 960-974. doi: 10.1016/S1388- 2457(99)00032-2
102. Schmitz, G., and Ecker, J. (2008). The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47, 147-155. doi: 10.1016/j.plipres.2007.12.004.
103. Sharp, P. S., Dick, J. R., and Greensmith, L. (2005). The effect of peripheral nerve injury on disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience 130, 897-910. doi: 10.1016/j.neuroscience.2004.09.069.
104. Shatunov, A., Mok, K., Newhouse, S., Weale, M. E., Smith, B., Vance, C., et al. (2010). Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 9, 986-994. doi: 10.1016/S1474-4422(10)70197-6.
105. Shimizu, T., Nagaoka, U., Nakayama, Y., Kawata, A., Kugimoto, C., Kuroiwa, Y., et al. (2012). Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: amulticenter studyinJapan. Amyotroph. Lateral Scler. 13, 363-366. doi: 10.3109/17482968.2012.678366.
106. Siciliano, G., D'Avino, C., Del Corona, A., Barsacchi, R., Kusmic, C., Rocchi, A., et al. (2002). Impaired oxidative metabolism and lipid peroxidation in exercising muscle from alS patients. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 3, 57-62. doi: 10.1080/146608202760196011.
107. Simons, K., and Vaz, W. L. (2004). Model systems, lipid rafts, and cell membranes. Annu. Rev. Biophys. Biomol. Struct. 33, 269-295. doi: 10.1146/annurev.biophys. 32.110601.141803
108. Singh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N. F., et al. (2006). Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T- cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147, 141-154. doi: 10.1210/en.2004-1649.
109. Song, Y., Nagy, M., Ni, W., Tyagi, N. K., Fenton, W. A., Lopez-Giraldez, F., et al. (2013). Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an alS-associated mutant SOD1 protein in squid axoplasm. Proc. Natl. Acad. Sci. U.S.A. 110, 5428-5433. doi: 10.1073/pnas.1303279110.
110. Sproule, D. M., Montes, J., Montgomery, M., Battista, V., Koenigsberger, D., Shen, W., et al. (2009). Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul. Disord. 19, 391-396. doi: 10.1016/j.nmd.2009.03.009.
111. Swoboda, K. J., Scott, C. B., Crawford, T. O., Simard, L. R., Reyna, S. P., Krosschell, K. J., et al. (2010). SMA CARNI-Val trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS ONE 5:e12140. doi: 10.1371/journal.pone.0012140.
112. Tein, I., Sloane, A. E., Donner, E. J., Lehotay, D. C., Millington, D. S., and Kelley, R. I. (1995). Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? Pediatr. Neurol. 12, 21-30. doi: 10.1016/0887-8994(94)00100-G
113. Thau, N., Knippenberg, S., Korner, S., Rath, K. J., Dengler, R., and Petri, S. (2012). Decreased mRNA expression ofPGC-1alpha and PGC-1alpha-regulated factors in the SOD1G93A alS mouse model and in human sporadic alS. J. Neuropathol. Exp. Neurol. 71, 1064-1074. doi: 10.1097/NEN.0b013e318275df4b
114. Walford, R. L., Mock, D., Verdery, R., and MacCallum, T. (2002). Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J. Gerontol. A Biol. Sci. Med. Sci. 57, B211-B224. doi: 10.1093/gerona/57.6.B211.
115. Xiao, Q., Pepe, A. E., Wang, G., Luo, Z., Zhang, L., Zeng, L., et al. (2012). Nrf3-Pla2g7 interaction plays an essential role in smooth muscle differentiation from stem cells. Arterioscler. Thromb. Vasc. Biol. 32, 730-744. doi: 10.1161/ATVBAHA.111.243188.
116. Xu, X., Bittman, R., Duportail, G., Heissler, D., Vilcheze, C., and London, E. (2001). Effect of the structure of natural sterols and sphingolipids on the formation of ordered sphingolipid/sterol domains (rafts). Comparison of cholesterol to plant, fungal, and disease-associated sterols and comparison of sphingomyelin, cerebrosides, and ceramide. J. Biol. Chem. 276, 33540-33546. doi: 10.1074/jbc.M104776200.
117. Yao, J. K., Cannon, K. P., Holman, R. T., and Dyck, P. J. (1983). Effects of polyunsaturated fatty acid diets on plasma lipids of patients with adrenomultineuronal degeneration, hepatosplenomegaly and fatty acid derangement. J. Neurol. Sci. 62, 67-75. doi: 10.1016/0022-510X(83)90190-9.
118. Yi, C. X., Habegger, K. M., Chowen, J. A., Stern, J., and Tschop, M. H. (2011). A role for astrocytes in the central control ofmetabolism. Neuroendocrinology 93, 143-149. doi: 10.1159/000324888.
119. Yip, P. K., Pizzasegola, C., Gladman, S., Biggio, M. L., Marino, M., Jayasinghe, M., et al. (2013). The omega-3. FattyAcid eicosapentaenoic Acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS ONE 8:e61626. doi: 10.1371/journal.pone.0061626.
120. Yoshikawa, T., Shimano, H., Yahagi, N., Ide, T., Amemiya-Kudo, M., Matsuzaka, T., et al. (2002). Polyunsaturated fatty acids suppress sterol regulatory element- binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 277, 1705-1711. doi: 10.1074/jbc.M105711200.
121. Zhao, W., Varghese, M., Vempati, P., Dzhun, A., Cheng, A., Wang, J., et al. (2012). Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in alS disease. PLoS ONE 7:e49191. doi: 10.1371/journal.pone. 0049191
122. Zhao, W., Varghese, M., Yemul, S., Pan, Y., Cheng, A., Marano, P., et al. (2011). Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC- 1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol. Neurodegener. 6, 51. doi: 10.1186/1750-13 26-6-51
123. Zhao, Z., Lange, D. J., Voustianiouk, A., MacGrogan, D., Ho, L., Suh, J., et al. (2006). A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMCNeurosci. 7:29. doi: 10.1186/1471-2202-7-29.
124. Zhou, J., Yi, J., Fu, R., Liu, E., Siddique, T., Rios, E., et al. (2010). Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J. Biol. Chem. 285, 705-712. doi: 10.1074/jbc.M109.041319